Filing summary: Homology Medicines, Inc. Form 10-Q
Important identity discrepancy: The request identifies Q32 Bio Inc., but the supplied filing is for Homology Medicines, Inc. (Nasdaq: FIXX), for the quarter ended June 30, 2020, filed August 10, 2020. The figures and discussion below are for Homology Medicines, not Q32 Bio.
Business context and reporting period
Homology was a clinical-stage genetic medicines company developing gene therapy and nuclease-free gene-editing candidates for rare diseases. Its lead clinical candidate, HMI-102, was in the dose-escalation portion of a Phase 1/2 trial for phenylketonuria (PKU); HMI-103 for PKU and HMI-202 for metachromatic leukodystrophy were in IND-enabling studies. The company had no approved products and no product sales.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data. The filing reports collaboration revenue, not product revenue.
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Collaboration revenue | $0.567 | $0.392 | $1.155 | $0.662 |
| Research and development expense | $27.471 | $22.827 | $56.780 | $43.368 |
| General and administrative expense | $8.793 | $5.538 | $16.563 | $10.390 |
| Total operating expenses | $36.264 | $28.365 | $73.343 | $53.758 |
| Net loss | $35.340 | $26.270 | $70.671 | $50.122 |
| Net loss per share, basic and diluted | $0.78 | $0.61 | $1.56 | $1.25 |
| Operating cash used | — | $53.833 | $39.541 |
At June 30, 2020, cash and cash equivalents were $167.636 million and short-term investments were $39.007 million; restricted cash was $1.274 million. The company reported total cash, cash equivalents, short-term investments and restricted cash of $207.9 million in MD&A. Total assets were $258.238 million, total liabilities $63.534 million, and stockholders’ equity $194.704 million. It reported no debt. Current assets of $209.807 million compared with current liabilities of $19.564 million.
Management estimated that existing cash, cash equivalents and short-term investments would fund projected operating expenses and capital expenditures into the fourth quarter of 2021. This estimate depended on assumptions that could prove inaccurate. The company had a $150 million at-the-market equity program available but had made no sales under it in the first half of 2020.
Material changes versus prior comparable periods
- Six-month net loss widened by $20.549 million year over year, as operating expenses rose $19.585 million and lower interest income partly offset higher collaboration revenue.
- Six-month R&D expense increased $13.412 million, mainly from HMI-102 clinical and manufacturing work, HMI-103 and HMI-202 development, and increased staffing. G&A expense rose $6.173 million.
- Operating cash use increased to $53.833 million from $39.541 million. Investing cash inflow was $167.007 million, primarily because investment maturities exceeded purchases; it should not be read as operating cash generation.
- Cash, cash equivalents and short-term investments declined from $262.388 million at December 31, 2019 to $206.643 million at June 30, 2020, before restricted cash. The 2019 comparison included substantial follow-on offering proceeds; there was no comparable public offering in the first half of 2020.
- The company adopted lease accounting Topic 842 on January 1, 2020, recognizing right-of-use assets and operating lease liabilities. Management said adoption did not materially affect operations.
Outlook, commentary, risks and unusual items
- Management expected operating expenses and capital expenditures to increase as clinical, preclinical, manufacturing, hiring and intellectual-property activities advanced; it did not provide numerical earnings or revenue guidance.
- COVID-19 had delayed enrollment and dosing in the HMI-102 pheNIX trial, extending the dose-escalation timeline before dose selection and expansion. The company reported using remote patient services and said its manufacturing facility was operating near normal levels.
- In the first quarter, the company accelerated purchases of raw materials to mitigate potential supply-chain interruptions. It said these purchases contributed to higher first-half operating costs.
- Reported HMI-102 preliminary clinical observations included no treatment-related serious adverse events reported to date and encouraging data suggesting PAH enzymatic activity. These early findings are not proof of efficacy; the filing cautions that preliminary data may change.
- Novartis confirmed an ophthalmic target in May 2020, and the parties were advancing toward development-candidate selection. The agreement provides for potential milestone payments and royalties, but these are contingent; the filing excluded milestone amounts from the recognized transaction price because they were constrained.
- Key risks include clinical efficacy and safety uncertainty, trial enrollment and COVID-19 disruption, manufacturing and supplier constraints, regulatory uncertainty, competition, intellectual-property disputes, and the need to raise additional capital. Management said the company would need capital beyond its estimated runway absent significant recurring revenue.
- No material legal proceedings were reported. The filing also stated there were no off-balance-sheet arrangements and no material changes in contractual obligations.
Important facts for investors to verify
- Confirm the issuer: this is Homology Medicines’ filing, not a Q32 Bio filing.
- Check subsequent filings and disclosures for actual cash runway, financing activity, and changes to the fourth-quarter 2021 runway estimate.
- Verify subsequent HMI-102 trial enrollment, dose-escalation timing, safety findings, and final clinical data against the preliminary observations in this report.
- Track HMI-103 and HMI-202 IND-enabling progress, and whether the Novartis ophthalmic program advances or produces contingent payments.
- Assess the drivers and sustainability of R&D spending, cash burn, and the potential dilution from use of the available ATM program.